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Psoriasis is a chronic skin disease in which genetics play a major role. Although many genome-wide association studies have been
performed in psoriasis, knowledge of the age at onset remains limited.Therefore, we analyzed 173 single-nucleotide polymorphisms
in genes associatedwith psoriasis and other autoimmune diseases in patients withmoderate-to-severe plaque psoriasis type I (early-
onset, <40 years) or type II (late-onset, ≥40 years) and healthy controls. Moreover, we performed a comparison between patients
with type I psoriasis and patients with type II psoriasis. Our comparison of a stratified population with type I psoriasis (𝑛 = 155)
and healthy controls (𝑁 = 197) is the first to reveal a relationship between the CLMN, FBXL19, CCL4L, C17orf51, TYK2, IL13,
SLC22A4, CDKAL1, and HLA-B/MICA genes. When we compared type I psoriasis with type II psoriasis (𝑁 = 36), we found
a significant association between age at onset and the genes PSORS6, TNF-𝛼, FCGR2A, TNFR1, CD226, HLA-C, TNFAIP3, and
CCHCR1. Moreover, we replicated the association between rs12191877 (HLA-C) and type I psoriasis and between type I and type II
psoriasis. Our findings highlight the role of genetics in age of onset of psoriasis.
1. Introduction
Psoriasis is a chronic inflammatory skin disorder with a
major genetic component. The prevalence of chronic plaque
psoriasis is around 2% in the general population [1].Themany
genetic studies performed in recent years showed that genes
such as interleukin 23 receptor (IL23R) and IL12B and tumor
necrosis factor alpha (TNF𝛼) are closely associated with
psoriasis and related diseases such as rheumatoid arthritis,
psoriatic arthritis, and Crohn’s disease [2]. Human leukocyte
antigen C (HLA-C)∗0602 is the allele most closely associated
with this disease [3].
The age at onset of psoriasis follows a bimodal distribu-
tion [4]: type I psoriasis appears before the age of 40 years
(early-onset), with a peak at 16–22 years; type II psoriasis
appears after the age of 40 years (late-onset), with a peak at
57–60 years [5]. Type I psoriasis has been associated with
several single-nucleotide polymorphisms (SNPs) in genes
associated with the immune response (Table 1). For example,
HLA-C∗0602 ismore strongly associatedwith type I psoriasis
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than with type II psoriasis [5]. Although several association
studies have already been performed in psoriasis in both
populations (type I or type II psoriasis patients), knowledge
of age at onset remains limited and controversial (Table 1) [6].
Therefore, we performed a candidate gene study, where we
evaluated genetic susceptibility to type I or type II psoriasis
in patients withmoderate-to-severe chronic plaque psoriasis.
This approach may help us to identify SNPs previously
associated with psoriasis or other autoimmune diseases [2]
that are specific to type I or type II psoriasis. Furthermore, our
genetic study could improve our understanding of psoriasis
and of its etiology and pathogenesis.
2. Material and Methods
2.1. Experimental Design. We recruited 198 Caucasian
patients with moderate-to-severe plaque type psoriasis
(psoriasis area and severity index > 10) who attended the
department of dermatology in four university hospitals in
Madrid between 16/10/2007 and 17/12/2012. Five samples
did not fulfill the quality criteria of the Human Genotyping
Unit-CeGen (CEGEN, Spanish National Cancer Research
Centre, Madrid, Spain), and 2 samples had insufficient
volume. We also included 197 healthy volunteers (controls)
recruited between 10/01/2011 and 14/12/2012 from the Clinical
Pharmacology Service (Hospital Universitario de la Princesa,
Madrid, Spain). All the volunteerswereCaucasian andhadno
personal or family history of psoriasis (at least 2 generations).
The protocol fulfilled Spanish law on biomedical research
and was approved by the Ethics Committee for Clinical
Investigation of Hospital Universitario de la Princesa. All
controls and patients gave their written informed consent to
donate a sample for investigation.The samples are kept in the
Clinical Pharmacology Service.
2.2. Selection of the Polymorphisms. We preselected 320 SNPs
based on an extensive review of 449 articles describing
the association between polymorphisms and psoriasis and
response to biological drugs and psoriasis and related inflam-
matory diseases (rheumatoid arthritis, psoriatic arthritis, and
Crohn’s disease) [2]. We finally selected 192 SNPs based on
minor allele frequency (≥0.05) and on the results of studies
performed in Caucasians and psoriatic patients. Information
on the 173 SNPs analyzed can be found in supplementary
Table S1, which is published in [3].
2.3. Sample Processing. A 3-mL peripheral blood sample
was extracted from each subject in EDTA tubes. DNA was
obtained from samples using an automatic DNA extractor
(MagNa Pure System, Roche Applied Science, USA) and its
concentration was quantified in Nanodrop ND-1000 Spec-
trophotometer (Wilmington, USA). The extracted DNA was
stored at −80∘C in the Clinical Pharmacology Service until
use.
2.4. Genotyping. A total of 196 samples from patients (2
samples of 198 cases had insufficient volume) and 197 samples
from controls were sent to the Human Genotyping Unit-
CeGen to genotype 192 SNPs. The analysis was performed
using the Illumina Veracode genotyping platform. If fluores-
cence was low or the genotype clusters were undifferentiated,
the SNPs were removed. In addition, if the call rate was less
than 95% of the average of the 192 SNPs analyzed, the samples
were removed. Since CEGEN quality criteria were not met in
19 SNPs and 5 patients, we finally analyzed 173 SNPs in 191
patients and 197 controls.
2.5. Statistical Analysis. The statistical analysis was per-
formed to compare the following stratified populations:
patients with type I psoriasis (𝑁 = 155) or type II psoriasis
(𝑁 = 36) versus controls (𝑁 = 197) and patients with type I
psoriasis versus cases with type II psoriasis. Hardy-Weinberg
equilibrium was tested for all the SNPs analyzed using the
SNPStats program [32]. Allele and genotype frequencies were
also calculated using the SNPStats program. SNPs that were
not inHardy-Weinberg equilibrium in controls were removed
from the subsequent analysis [33].
The univariate analysis was performed using R 3.0.2.
(SNPassoc) [34]. We constructed various logistic regression
models depending on the main types of inheritance (codom-
inant, dominant, recessive, and additive). In the additive
model, the presence of 2mutant alleles confers double the risk
of 1mutant allele [33].The results were adjusted for rs12191877
(SNP that is strongly associated with the HLA-C∗0602 allele
and is highly prevalent in our population) [3, 35].The optimal
model was selected using the lower Akaike Information
Criterion (AIC). Subsequently, SNPs with 𝑝 < 0.1 in the
univariate analysis (adjusted for rs12191877) were included
in a multivariate logistic regression model to adjust for
relevant confounding factors (SPSS 15.0). The results of the
univariate analysis were adjusted for rs12191877, except when
we compared patients with type I psoriasis and patients with
type II psoriasis (the influence of rs12191877 was not very
relevant). We expressed the results as the odds ratio (OR),
95% confidence interval, and 𝑝 value.
3. Results
3.1. Study Population. The study population included 155
patients withmoderate-to-severe chronic plaque type I psori-
asis (92men and 63women), 36 patients with type II psoriasis
(19 men and 17 women), and 197 controls (98 men and 99
women). The mean age was 46.01 ± 13.11 years in patients
with type I psoriasis (45.72±11.69 inmen and 46.43±15.04 in
women), 67.72 ± 11.85 years in patients with type II psoriasis
(65.95 ± 11.18 in men and 69.71 ± 12.59 in women), and
24.51 ± 4.29 years in the controls (25.07 ± 4.94 in men and
23.95±3.46 inwomen).Themean age at onset of psoriasis was
23.31±8.52 in patients with type I psoriasis and 52.58±10.45
in patients with type II psoriasis. Analysis of the effect of sex
on our results revealed no significant association.
3.2. Genotyping Results. A total of 192 SNPs were analyzed
(see supplementary Table S1 published in [3]). However,
only 173 SNPs fulfilled the quality criteria. One SNP was
monomorphic (rs165161 in the JUNB gene) and was excluded
from the statistical analysis. The genotyping success rate was
89.82%, and the reproducibility rate was 100%.
Journal of Immunology Research 5
Table 2: Results of univariate linear regression analysis (unadjusted and adjusted for rs12191877 inHLA-C) andmultivariate linear regression
analysis (155 patients with type I psoriasis versus 197 controls). In themultivariate analysis, we included the SNPswith𝑝 < 0.1 in the univariate
analysis adjusted for HLA-C. Only polymorphisms that were significant in the multivariate analysis are shown.
SNP Gene Model Riskgenotype
Univariate unadjusted. Type I
patients versus controls
Univariate adjusted for
HLA-C Multivariate
OR (95% CI) 𝑝 value OR (95% CI) 𝑝 value OR (95% CI) 𝑝 value
rs2282276 CLMN A CC/CT 1.74 (0.96–3.15) 0.066 1.95 (1.04–3.65) 0.037 3.90 (1.13–13.38) 0.031
rs10782001 FBXL19 A GG/AG 1.58 (1.13–2.21) 0.007 1.59 (1.09–2.32) 0.016 2.10 (1.05–4.17) 0.035
rs1634517 CCL4L D AA/AC 0.89 (0.58–1.36) 0.590 0.64 (0.39–1.05) 0.073 0.34 (0.14–0.84) 0.019
rs1975974 C17orf51 A GG/AG 0.80 (0.57–1.14) 0.220 0.66 (0.44–0.99) 0.040 0.48 (0.23–0.99) 0.048
rs12720356 TYK2 A GG/GT 0.42 (0.21–0.81) 0.019 0.27 (0.13–0.58) 0.0003 0.10 (0.03–0.39) 0.001
rs1800925 IL13 R TT 0.18 (0.02–1.45) 0.051 0.17 (0.02–1.49) 0.061 0.01 (0.00–0.73) 0.034
rs3792876 SLC22A4 A TT/CT 1.57 (0.89–2.76) 0.110 1.87 (0.98–3.55) 0.057 3.75 (1.19–11.83) 0.024
rs6908425 CDKAL1 A TT/CT 0.67 (0.47–0.97) 0.029 0.58 (0.39–0.89) 0.01 0.41 (0.20–0.85) 0.017
rs12191877 HLA-C A TT/CT 5.92 (3.83–9.15) 2.50𝐸 − 19 — — 30.54 (10.62–87.85) 0.000
rs13437088 HLA-B/MICA D TT/CT 2.17 (1.42–3.34) 3.00𝐸 − 04 1.93 (1.19–3.13) 0.007 2.52 (1.01–6.31) 0.048
CLMN: calponin-like transmembrane gene; FBXL19: F-box and leucine-rich repeat protein 19; CCL4L: chemokine (C-C motif) ligand 4-like; C17orf51:
chromosome 17 open reading frame 51; TYK2: nonreceptor tyrosine-protein kinase; IL13: interleukin 13; SLC22A4: solute carrier family 22member 4; CDKAL1:
cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1; HLA: major histocompatibility complex; MICA: major histocompatibility complex
class I polypeptide-related sequence A; SNPs: single-nucleotide polymorphisms; OR: odds ratio of presenting type 1 psoriasis; CI: confidence interval; A:
additive; R: recessive; D: dominant; —: no data.
All the minor allele frequencies were in Hardy-Weinberg
equilibrium except 9 SNPs in the controls and 12 SNPs in the
patients (see supplementary Table S1 published in [3]). The
9 SNPs which were not in Hardy-Weinberg equilibrium in
controls were removed from the statistical analysis [33].
3.3. Association with Type I or Type II Psoriasis. Our findings
showed an association between type I psoriasis and 10 SNPs
(𝑁 = 155 versus 𝑁 = 197 controls): rs1634517 (CCL4L),
rs1975974 (C17orf51), rs12720356 (TYK2), rs1800925 (IL13),
and rs6908425 (CDKAL1) decreased the risk of psoriasis 2.94-
fold, 2.08-fold, 10-fold, 100-fold, and 2.44-fold, respectively;
and rs2282276 (CLMN), rs10782001 (FBXL19), rs3792876
(SLC22A4), rs12191877 (HLA-C), and rs13437088 (HLA-
B/MICA) increased the risk of psoriasis 3.90-fold, 2.10-fold,
3.75-fold, 30.54-fold, and 2.52-fold, respectively (Table 2).
However, comparison of 36 patients with type II psoriasis and
197 controls revealed no significant association (results not
shown).
Four SNPs were associated with significant decreases in
the risk of type I psoriasis (𝑁 = 155) compared with type
II psoriasis (𝑁 = 36), namely, rs191190 (TNFR1; 126.08-fold),
rs361525 (TNF-𝛼; 190.76-fold), and rs10499194 and rs6920220
(TNFAIP3; 155.02-fold and 19.14-fold, resp.). We also found 5
SNPs that were associated with a significant increase in the
risk of type I psoriasis, namely, rs1801274 (FCGR2A; 5.26-
fold), rs763361 (CD226; 33.3-fold), rs12459358 (PSORS6; 11.11-
fold), rs12191877 (HLA-C; 12.5-fold), and rs1576 (CCHCR1;
166.66-fold) (Table 3).
4. Discussion
About 75% of patients with chronic plaque psoriasis have
type I psoriasis before age 40 [4], whereas a lower number
of patients develop psoriasis at around 50–60 years [11]. Our
results are consistent with these findings, since 79.06% of our
patients developed psoriasis before the age of 40.
When we compared patients with type I psoriasis and
controls, we found 10 significant SNPs in CLMN, FBXL19,
CCL4L, C17orf51, TYK2, IL13, SLC22A4, CDKAL1, HLA-C,
and HLA-B/MICA.
The HLA-C∗0602 allele is a risk factor for psoriasis
[35] and has been associated with both type I [6–9] and
type II psoriasis [10]. In one study, 85.3% of patients with
type I psoriasis had this allele [5], whereas only 14.7% of
patients with type II psoriasis were carriers [5]. Other authors
found an association between rs10484554 (HLA-C) and type
I psoriasis compared with type II psoriasis (OR = 3.24
in type I) [12]. rs10484554 has also been associated with
type II psoriasis [10]. In a recent GWAS, the HLA-C gene
was associated with type I psoriasis (𝑝 = 2.97𝐸 − 18 for
rs1265181, 𝑝 = 2.58𝐸 − 15 for rs12191877, 𝑝 = 1.84𝐸 − 15 for
rs4406273, and 𝑝 = 1.10𝐸 − 07 for rs2395029), but not with
type II psoriasis after application of the Bonferroni correction
[11]. In addition, our results showed significant differences in
rs12191877 (HLA-C) in patients with type I psoriasis (𝑝 =
2.50𝐸 − 19). However, we did not find this association in
patients with type II psoriasis, probably owing to the small
sample size in this group (𝑁 = 36).
Munir et al. found an association between rs1295685 in
the IL13 gene and type I psoriasis (𝑝 = 2.47𝐸 − 03) [11]. Our
results showed an association between another SNP in IL13
(rs1800925) and type I psoriasis (𝑝 = 0.034). In addition,
Munir et al. did not obtain significant results when they
compared controls with type II psoriasis or type I psoriasis
with type II psoriasis [11]. Both SNPs in IL13 have been
associated with predisposition to psoriasis [36, 37].
Our comparison of patients with type I psoriasis and
controls is the first to obtain significant results for a series
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Table 3: Results of univariate andmultivariate linear regression analyses (155 patients with psoriasis type I versus 36 cases with psoriasis type
II). SNPs with 𝑝 < 0.1 in the univariate analysis were included in the multivariate analysis. Only polymorphisms that were significant in the
multivariate analysis are shown.
SNP Gene Model Risk genotype Univariate Ps patients type I versus type II Multivariate
OR (95% CI) 𝑝 value OR (95% CI) 𝑝 value
rs1801274 FCGR2A A CC/CT 1.96 (1.12–3.45) 0.016 5.26 (1.11–25) 0.037
rs191190 TNFR1 D CC/CT 0.43 (0.17–1.11) 0.065 0.01 (1.44E − 04–0.44) 0.018
rs763361 CD226 D TT/CT 2.08 (0.99–4.35) 0.056 33.33 (1.11–1000) 0.043
rs12459358 PSORS6 A TT/CT 2.44 (1.32–4.55) 0.002 11.11 (1.32–100) 0.026
rs10499194 TNFAIP3 D TT/CT 0.38 (0.17–0.90) 0.02 0.01 (6.77E − 05–0.61) 0.030
rs12191877 HLA-C A TT/CT 2.33 (1.23–4.35) 0.006 12.50 (1.06–100) 0.045
rs6920220 TNFAIP3 A AA/AG 0.55 (0.30–1.03) 0.068 0.05 (0.003–0.90) 0.042
rs361525 TNF-𝛼 C AG 2.17 (0.62–7.69) 0.087 0.01 (5.48E − 05–0.50) 0.024
rs1576 CCHCR1 D GG/GC 2.56 (1.22–5.26) 0.012 166.67 (2.32–1000) 0.019
FCGR2A: Fc fragment of IgG low affinity IIa receptor; TNFR1: tumor necrosis factor receptor 1; CD226: CD226 antigen; PSORS6: psoriasis susceptibility 6;
TNFAIP3: tumor necrosis factor alpha-induced protein 3; HLA-C: major histocompatibility complex; TNFAIP3: tumor necrosis factor alpha-induced protein
3; TNF-𝛼: tumor necrosis factor alpha; CCHCR1: coiled-coil alpha-helical rod protein 1; SNPs: single-nucleotide polymorphisms; OR: odds ratio of presenting
type I psoriasis; CI: confidence interval; A: additive; D: dominant; C: codominant.
of SNPs in type I psoriasis, although the SNPs have already
been associated with the risk of psoriasis. rs10782001 in
FBXL19 [38], rs1975974 in C17orf51 [38], rs12720356 in TYK2
[3, 39], rs3792876 in SLC22A4 [3], rs6908425 in CDKAL1
[40], and rs13437088 in HLA-B/MICA [35] have previously
been associated with psoriasis, but not with type I psoriasis.
Furthermore, SNPs in CLMN (rs2282276) and CCL4L
(rs1634517) have not been associated with psoriasis or age at
onset.
We found no significant differences between patients with
type II psoriasis and controls owing to the small sample size
(𝑁 = 36).
Comparison between patients with type I psoriasis and
patients with type II psoriasis revealed significant associ-
ations for the following genes: FCGR2A, TNFR1, CD226,
PSORS6, TNFAIP3, HLA-C, TNF-𝛼, and CCHCR1.
Polymorphisms in CCHCR1 (−386 and −404,
CCHCR1∗WW allele) have been associated with type I
psoriasis [9, 31]. We found significant differences between
rs1576 in CCHCR1 and age at onset. In a study comparing
controls (54.8%) and patients with psoriasis type II (66.0%),
Allen et al. showed a significant increase in the number of
patients carrying rs1576 [41]. This SNP has been associated
with psoriasis elsewhere [42].
Douroudis et al. analyzed rs763361 in CD226 in patients
with early-onset psoriasis and patients with late-onset psori-
asis, although they found no associations [43].We performed
the same analyses and found significant differences between
the groups. In addition, rs763361 in CD226 has been associ-
ated with severity of psoriasis [43].
rs12459358 in PSORS6 has been associated with type I
psoriasis (G risk allele, OR = 1.47 and 𝑝 = 0.005) [19]. In
contrast, our data showed an association between the T allele
and type I psoriasis (OR = 11.11; 𝑝 = 0.026).
rs361525 (−238) in the TNF𝛼 gene has been associated
with susceptibility to psoriasis [44], and the A allele was
more frequent in male patients with type I psoriasis (𝑝 =
2𝐸 − 07) [15, 22]. We found significant results in rs361525
(TNF-𝛼) when we compared patients with type I psoriasis
and patients with type II psoriasis, although we found no
gender differences. Other authors confirmed our association
with type I psoriasis in Caucasian [20, 23] and Mongolian
patients [24]. Ameta-analysis showed an association between
rs361525 and type I psoriasis [21]. Baran et al. found no sig-
nificant differences between rs1800629 in the −308 promoter
(TNF𝛼) and type I or type II psoriasis [45].
Likewise, rs12191877 in HLA-C has been associated with
increased risk of psoriasis [35]. Munir et al. [11] compared
patients with type I psoriasis and patients with type II psoria-
sis and obtained significant results for rs1265181, rs4406273,
and rs12191877 in HLA-C. We replicated these results in
rs12191877 (T allele risk; 𝑝 = 0.045).
rs191190 in TNFR1 [46] and rs10499194 in TNFAIP3 [3]
have been associated with psoriasis, but not with age of onset.
Moreover, rs1801274 in FCGR2A and rs6920220 in TNFAIP3
have not been studied in patients with psoriasis according to
age of onset. Given the small sample size in the group with
type II psoriasis in our study, our results should be interpreted
with caution.
Our results highlight the role of the immune system
in psoriasis and enhance our understanding of pathogenic
mechanisms. Such knowledge can help to optimize treat-
ment.
Our study is subject to a series of limitations. First, mean
age varied between the cases and the controls. Second, the
sample size was limited by the number of study patients
treated in the dermatology department, thus making it
difficult to detect SNPs with a low probability of causing
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psoriasis. Third, since the SNPs were selected based on a
literature review, several major SNPs may not yet have been
investigated.
In conclusion, our study confirmed an association
between rs12191877 (HLA-C) and type I psoriasis and
between type I and type II psoriasis patients. Ours is
the first study to show an association between CLMN,
FBXL19, CCL4L, C17orf51, TYK2, IL13, SLC22A4, CDKAL1,
and HLA-B/MICA and type I psoriasis. Moreover, CLMN
and CCL4L have not been previously described in psoriasis.
In addition, PSORS6 and TNF𝛼 have been described as
more prevalent genes in type I psoriasis and we showed a
significant association when we compared type I psoriasis
and type II psoriasis. Ours is the first study to identify
an association between FCGR2A, TNFR1, CD226, TNFAIP3,
and CCHCR1 and age at onset of psoriasis. Our results
suggest that genetics could play a role in age at onset.
However, further studies are needed to confirm our find-
ings.
Conflict of Interests
E. Daude´n has potential conflict of interests (advisory board
member, consultant, grants, research support, participation
in clinical trials, honoraria for speaking, and research sup-
port) with the following pharmaceutical companies: Abb-
Vie (Abbott), Amgen, Janssen-Cilag, Leo Pharma, Novar-
tis, Pfizer, MSD, and Celgene. F. Abad-Santos has been
a consultant or investigator in clinical trials sponsored
by the following pharmaceutical companies: Abbott, Alter,
Chemo, Faes, Farmal´ıder, Ferrer, GlaxoSmithKline, Janssen-
Cilag, Kern, Normon, Servier, Teva, and Zambon. P. de la
Cueva has conflict of interests (advisory board member,
consultant, grants, research support, participation in clinical
trials, honoraria for speaking, and/or research support) with
the following pharmaceutical companies: AbbVie (Abbott),
Astellas, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD,
Gebro, Isdin, and Lilly. J. L. Lo´pez Estebaranz has conflict
of interests (advisory board member, speaker, or participa-
tion in clinical trials) with AbbVie, Amgen, Pfizer, MSD,
Janssen-Cilag, Lilly, Celgene. Ofelia Baniandre´s has conflict
of interests (participation in clinical trials and honoraria
for speaking) with the following pharmaceutical companies:
AbbVie (Abbott), Janssen-Cilag, Leo Pharma, Pfizer, and
MSD.
Authors’ Contribution
Roc´ıo Prieto-Pe´rez and Guillermo Solano-Lo´pez contributed
equally to the paper.
Acknowledgments
This work was supported by Instituto de Salud Carlos III
(FIS PI10/01740), Fundacio´n Teo´filo Hernando, and AbbVie.
Roc´ıo Prieto-Pe´rez has a grant from University Auto´noma
de Madrid (FPI Program 2013). The authors are grateful
to Thomas O’Boyle for editorial assistance and to Cristina
Carazo for helping to set up the patient databases.
References
[1] V. Chandran, “Genetics of psoriasis and psoriatic arthritis,”
Indian Journal of Dermatology, vol. 55, no. 2, pp. 151–156, 2010.
[2] R. Prieto-Pe´rez, T. Cabaleiro, E. Daude´n, and F. Abad-Santos,
“Gene polymorphisms that can predict response to anti-TNF
therapy in patients with psoriasis and related autoimmune
diseases,” Pharmacogenomics Journal, vol. 13, no. 4, pp. 297–305,
2013.
[3] R. Prieto-Pe´rez, G. Solano-Lo´pez, T. Cabaleiro et al., “New
immune system genetic polymorphisms associated with mod-
erate-to-severe plaque psoriasis: a case-control study,” British
Journal of Dermatology, vol. 172, no. 5, pp. 1432–1435, 2015.
[4] H. He´bert, J. Bowes, R. Smith et al., “Identification of loci asso-
ciated with late-onset psoriasis using dense genotyping of im-
mune-related regions,” British Journal of Dermatology, vol. 172,
no. 4, pp. 933–939, 2015.
[5] T. Henseler and E. Christophers, “Psoriasis of early and late
onset: characterization of two types of psoriasis vulgaris,”
Journal of the American Academy of Dermatology, vol. 13, no.
3, pp. 450–456, 1985.
[6] J. G. M. Bergboer, A. M. Oostveen, M. E. A. de Jager et al.,
“Paediatric-onset psoriasis is associated with ERAP1 and IL23R
loci, LCE3C LCE3B deletion and HLA-C∗06,” British Journal of
Dermatology, vol. 167, no. 4, pp. 922–925, 2012.
[7] Y. Lu, S. Kane, H. Chen et al., “The role of 39 psoriasis risk
variants on age of psoriasis onset,” ISRNDermatology, vol. 2013,
Article ID 203941, 4 pages, 2013.
[8] T. Mabuchi, T. Ota, Y. Manabe et al., “HLA-C∗12:02 is a sus-
ceptibility factor in late-onset type of psoriasis in Japanese,”
Journal of Dermatology, vol. 41, no. 8, pp. 697–704, 2014.
[9] Y.-T. Chang, H. N. Liu, Y. M. Shiao et al., “A study of PSORS1C1
gene polymorphisms in Chinese patients with psoriasis,” British
Journal of Dermatology, vol. 153, no. 1, pp. 90–96, 2005.
[10] J. Lysell, L. Padyukov, I. Kockum, P. Nikamo, and M. Sta˚hle,
“Genetic association with ERAP1 in psoriasis is confined to
disease onset after puberty and not dependent on HLA-C∗06,”
Journal of Investigative Dermatology, vol. 133, no. 2, pp. 411–417,
2013.
[11] S. Munir, S. B. Rahman, S. Rehman et al., “Association analysis
of GWAS and candidate gene loci in a Pakistani populationwith
psoriasis,” Molecular Immunology, vol. 64, no. 1, pp. 190–194,
2015.
[12] S. Masouri, I. Stefanaki, K. P. Kypreou et al., “Replication of
risk variants for psoriasis in a Southern European case-control
study: correlation with clinical subphenotypes,” British Journal
of Dermatology, vol. 173, no. 2, pp. 552–554, 2015.
[13] L. Xu, Y. Li, X. Zhang et al., “Deletion of LCE3C and LCE3B
genes is associated with psoriasis in a northern Chinese popula-
tion,”British Journal of Dermatology, vol. 165, no. 4, pp. 882–887,
2011.
[14] O. Haase, H. Mosaad, M. A. Eldarouti et al., “TNFAIP3 and
IL12B gene polymorphisms associated with psoriasis vulgaris
in an Egyptian cohort,” Journal of the European Academy of
Dermatology and Venereology, vol. 29, no. 7, pp. 1297–1301, 2015.
[15] K. Reich, R. Mo¨ssner, I. R. Ko¨nig, G. Westphal, A. Ziegler, and
C. Neumann, “Promoter polymorphisms of the genes encoding
tumor necrosis factor-𝛼 and interleukin-1𝛽 are associated with
different subtypes of psoriasis characterized by early and late
disease onset,” Journal of Investigative Dermatology, vol. 118, no.
1, pp. 155–163, 2002.
8 Journal of Immunology Research
[16] P. Nikamo, S. Cheuk, J. Lysell et al., “Genetic variants of the
IL22 promoter associate to onset of psoriasis before puberty and
increased IL-22 production in T cells,” Journal of Investigative
Dermatology, vol. 134, no. 6, pp. 1535–1541, 2014.
[17] R. B. Warren, R. L. Smith, E. Flynn et al., “A systematic investi-
gation of confirmed autoimmune loci in early-onset psoriasis
reveals an association with IL2/IL21,” British Journal of Derma-
tology, vol. 164, no. 3, pp. 660–664, 2011.
[18] C. Ronpirin, T. Tencomnao, and J. Wongpiyabovorn, “Associa-
tion between the -1438A/G polymorphism of the serotonin 2A
receptor gene and late-onset psoriasis in a Thai population,”
Genetics andMolecular Research, vol. 9, no. 1, pp. 208–214, 2010.
[19] U. Hu¨ffmeier, J. Lascorz, T. Becker et al., “Characterisation of
psoriasis susceptibility locus 6 (PSORS6) in patients with early
onset psoriasis and evidence for interactionwith PSORS1,” Jour-
nal of Medical Genetics, vol. 46, no. 11, pp. 736–744, 2009.
[20] B. Nedoszytko, A. Szczerkowska-Dobosz, M. Zabłotna, J. Glen´,
K. Rębała, and J. Roszkiewicz, “Associations of promoter region
polymorphisms in the tumour necrosis factor-𝛼 gene and early-
onset psoriasis vulgaris in a northern Polish population,” British
Journal of Dermatology, vol. 157, no. 1, pp. 165–167, 2007.
[21] Y. Jia, H. J. Qin, J. X. Zhang, X. L. Liu, and L. J. Li, “Association
of the tumour necrosis factor-𝛼 polymorphisms rs361525 and
rs1800629 with susceptibility to psoriasis: a meta-analysis,”
Clinical and Experimental Dermatology, vol. 38, no. 8, pp. 836–
844, 2013.
[22] K. Reich, G. Westphal, T. Schulz et al., “Combined analysis of
polymorphisms of the tumor necrosis factor-𝛼 and interleukin-
10 promoter regions and polymorphic xenobiotic metabolizing
enzymes in psoriasis,” Journal of Investigative Dermatology, vol.
113, no. 2, pp. 214–220, 1999.
[23] T. Hohler, A. Kruger, P. M. Schneider et al., “A TNF-alpha pro-
moter polymorphism is associated with juvenile onset psoriasis
and psoriatic arthritis,” Journal of InvestigativeDermatology, vol.
109, no. 4, pp. 562–565, 1997.
[24] F. Long, C. Sun, D. Deng, X. Zhou, X.-P. Li, and Y.-P. Zhang,
“TNF-238A is associated with juvenile onset psoriasis in
patients of Han population in Southwest China,” Journal of Der-
matological Science, vol. 36, no. 2, pp. 109–111, 2004.
[25] X. Zhang, Z. Fei, J. Wan, J. Xu, B. Yu, and M. Guan, “Associ-
ation analysis of BANK1 gene with psoriasis in Southern Han
Chinese,” International Journal of Immunogenetics, vol. 38, no.
6, pp. 507–512, 2011.
[26] J. Wu, F. Chen, X. Zhang et al., “Association of MIF promoter
polymorphisms with psoriasis in a Han population in north-
eastern China,” Journal of Dermatological Science, vol. 53, no. 3,
pp. 212–215, 2009.
[27] J. Wongpiyabovorn, N. Hirankarn, K. Ruchusatsawat, S. Yooy-
ongsatit, P. Asawanonda, and Y. Poovorawan, “Association of
the interleukin-10 distal promoter (-2763A/C) polymorphism
with late-onset psoriasis,” Clinical and Experimental Dermatol-
ogy, vol. 33, no. 2, pp. 186–189, 2008.
[28] N. M. Craven, C. W. Jackson, B. Kirby et al., “Cytokine gene
polymorphisms in psoriasis,” British Journal of Dermatology,
vol. 144, no. 4, pp. 849–853, 2001.
[29] W. Weger, A. Hofer, P. Wolf et al., “The angiotensin-converting
enzyme insertion/deletion and the endothelin -134 3A/4A gene
polymorphisms in patients with chronic plaque psoriasis,”
Experimental Dermatology, vol. 16, no. 12, pp. 993–998, 2007.
[30] S. Barile, E. Medda, L. Nistico` et al., “Vascular endothelial
growth factor gene polymorphisms increase the risk to develop
psoriasis,”ExperimentalDermatology, vol. 15, no. 5, pp. 368–376,
2006.
[31] Y. T. Chang, Y. M. Shiao, P. J. Chin et al., “Genetic polymor-
phisms of the HCR gene and a genomic segment in close
proximity to HLA-C are associated with patients with psoriasis
in Taiwan,” British Journal of Dermatology, vol. 150, no. 6, pp.
1104–1111, 2004.
[32] X. Sole´, E. Guino´, J. Valls, R. Iniesta, and V. Moreno, “SNPStats:
aweb tool for the analysis of association studies,”Bioinformatics,
vol. 22, no. 15, pp. 1928–1929, 2006.
[33] R. Iniesta, E. Guino´, and V. Moreno, “Statistical analysis of
genetic polymorphisms in epidemiological studies,” Gaceta
Sanitaria, vol. 19, no. 4, pp. 333–341, 2005.
[34] J. R.Gonza´lez, L. Armengol, X. Sole´ et al., “SNPassoc: anRpack-
age to performwhole genome association studies,” Bioinformat-
ics, vol. 23, no. 5, pp. 644–645, 2007.
[35] B.-J. Feng, L.-D. Sun, R. Soltani-Arabshahi et al., “Multiple
loci within the major histocompatibility complex confer risk
of psoriasis,” PLoS Genetics, vol. 5, no. 8, Article ID e1000606,
2009.
[36] M.Chang, Y. Li, C. Yan et al., “Variants in the 5q31 cytokine gene
cluster are associated with psoriasis,” Genes and Immunity, vol.
9, no. 2, pp. 176–181, 2008.
[37] S. Das, P. E. Stuart, J. Ding et al., “Finemapping of eight psoriasis
susceptibility loci,”European Journal of HumanGenetics, vol. 23,
no. 6, pp. 844–853, 2015.
[38] P. E. Stuart, R. P. Nair, E. ELinghaus et al., “Genome-wide asso-
ciation analysis identifies three psoriasis susceptibility loci,”
Nature Genetics, vol. 42, no. 11, pp. 1000–1004, 2010.
[39] A. Strange, F. Capon, C. C. Spencer et al., “A genome-wide asso-
ciation study identifies new psoriasis susceptibility loci and an
interaction between HLA-C and ERAP1,” Nature Genetics, vol.
42, no. 11, pp. 985–990, 2010.
[40] Y. Li, W. Liao, M. Chang et al., “Further genetic evidence for
three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22,”
Journal of Investigative Dermatology, vol. 129, no. 3, pp. 629–634,
2009.
[41] M. H. Allen, H. Ameen, C. Veal et al., “The major psoriasis
susceptibility locus PSORS1 is not a risk factor for late-onset
psoriasis,” Journal of Investigative Dermatology, vol. 124, no. 1,
pp. 103–106, 2005.
[42] S. Chantarangsu, T. Mushiroda, S. Mahasirimongkol et al.,
“Genome-wide association study identifies variations in 6p21.3
associated with nevirapine-induced rash,” Clinical Infectious
Diseases, vol. 53, no. 4, pp. 341–348, 2011.
[43] K. Douroudis, K. Kingo, H. Silm et al., “The CD226 Gly307Ser
gene polymorphism is associated with severity of psoriasis,”
Journal of Dermatological Science, vol. 58, no. 2, pp. 160–161,
2010.
[44] T. Cabaleiro, M. Roma´n, E. Gallo et al., “Association between
psoriasis and polymorphisms in the TNF, IL12B, and IL23R
genes in Spanish patients,” European Journal of Dermatology,
vol. 23, no. 5, pp. 640–645, 2013.
[45] W. Baran, J. C. Szepietowski, G. Mazur, and E. Baran, “A-
308 promoter polymorphism of tumor necrosis factor alpha
gene does not associate with the susceptibility to psoriasis
vulgaris. No difference either between psoriasis type I and type
II patients,” Acta Dermatovenerologica Alpina, Pannonica et
Adriatica, vol. 15, no. 3, pp. 113–118, 2006.
[46] R. Zenz, R. Eferl, L. Kenner et al., “Psoriasis-like skin disease
and arthritis caused by inducible epidermal deletion of Jun
proteins,” Nature, vol. 437, no. 7057, pp. 369–375, 2005.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
